Quigley Pharma

Quigley BioPharma is a privately held, US-based consultancy founded in 2005, offering deep expertise in vaccine and biological product development from preclinical stages through regulatory approval. The company's core business model is providing fee-for-service advisory and technical support to biotech and pharma clients, drawing on the extensive industry and government experience of its leadership team, notably vaccinologists Dr. Thomas Monath and Dr. Gray Heppner. While not a therapeutic developer itself, Quigley plays a critical role in de-risking and advancing external vaccine programs, particularly in complex areas like biodefense and tropical diseases.

Expertise-based consultancy platform for vaccine and biological therapeutic development, encompassing strategic guidance, regulatory strategy, and operational support across the entire product lifecycle.

Quigley competes in a crowded life science services market against large, full-service CROs (e.g., IQVIA, PPD) and other boutique consultancies. Its differentiation is the unparalleled, hands-on vaccine development pedigree of its founders, particularly in biodefense and tropical diseases, allowing it to command a premium for strategic advisory rather than operational execution alone.